Comparative Pharmacology
Head-to-head clinical analysis: EPTIFIBATIDE versus REOPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPTIFIBATIDE versus REOPRO.
EPTIFIBATIDE vs REOPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen and von Willebrand factor binding and thereby inhibiting platelet aggregation.
Reopro (abciximab) is a chimeric monoclonal antibody Fab fragment that binds to the glycoprotein IIb/IIIa receptor on activated platelets, thereby inhibiting platelet aggregation by blocking the binding of fibrinogen and von Willebrand factor.
Intravenous bolus of 180 mcg/kg followed by continuous infusion of 2 mcg/kg/min for up to 18 hours. For patients undergoing PCI, an additional 180 mcg/kg bolus 10 minutes after the first bolus is given.
0.25 mg/kg intravenous bolus over 5 minutes, followed by 0.125 mcg/kg/min (maximum 10 mcg/min) continuous intravenous infusion for 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours. In patients with moderate to severe renal impairment (CrCl <50 mL/min), half-life is prolonged to about 4.2 hours, necessitating dose adjustment.
Terminal half-life approximately 30 minutes (initial phase) with a second phase of about 4 hours due to slow dissociation from platelet glycoprotein IIb/IIIa receptors; clinical effect persists for platelet inhibition up to 24-48 hours after infusion cessation.
Renal excretion accounts for approximately 50% of total clearance, with about 30% excreted unchanged in urine. The remainder is metabolized and eliminated via biliary/fecal routes (~50%).
Renal (primarily via proteolytic degradation into small peptides and individual amino acids); <5% excreted unchanged in urine. Fecal elimination negligible.
Category A/B
Category C
Glycoprotein IIb/IIIa Inhibitor
Glycoprotein IIb/IIIa Inhibitor